Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Night Trader who wrote (14745)	7/4/2002 12:54:55 PM
From: 249443	Respond to of 78705

"I'm not too concerned with positive Cash flow as long as the burn rate is sustainable, particularly if most of it is in R+D." -----In aggregate, I just don't see too much of the R&D at smaller biotechs paying off. "However two of the ones I mentioned are already profitable; VASO and KDUS and a third will be within a year; EBIO." -----I would espouse this strategy as a company that is already profitable has, obviously, displayed an effective business model. This assumes that the profitability is a regular occurrence and not just a one-time situation. -----What bothers me most about these biotechs selling for less than cash, with a lot of patents, etc. is drugs are not moving through the pipeline. A lot of meaningless press releases and a lot of insider selling tells me to run. -----I've always been aware of Vic -- in more ways than one!